LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here ...

President Donald Trump is keeping up the pace with seemingly a new tariff development every day. This time, he flagged that ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

President Trump said he was likely to impose tariffs on pharmaceuticals as soon as the end of the month, starting with a "low ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity ...

The drugmaker has invested $10 billion in Wake and Durham counties over the past 30 years. Biogen says that figure will ...

Bank of America Securities analyst Tim Anderson maintained a Buy rating on Merck & Company today. The company’s shares opened today at $83.96. Elevate Your Investing Strategy: T ...